This study aimed to determine whether the second-generation cannabinoid receptor subtype 1 (CB1) antagonist, monlunabant - designed to treat obesity by targeting peripheral receptors - might actually exert its effects through CB1 receptors in the central nervo... ...

请注册登录后继续浏览